TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02386917

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: Weight loss surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very low calorie diet
Description: Non-surgical weight loss procedure
Study: NCT01017978

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Scan of soft tissue tumor
Description: MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
Study: NCT04031430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication
Description: Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CV profiling before and after the start/switch of antihypertensive medication
Description: CV profiling before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
Study: NCT04282564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-OP treatment
Description: The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-OP treatment
Description: The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-OP treatment
Description: The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke
Study: NCT04584359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA
Description: High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global osteopathic protocol
Description: Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global osteopathic protocol
Description: Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
Study: NCT03840200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered orally.
Study: NCT01357447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dornase alfa
Description: Dose: 2.5 mg solution BID via nebuliser for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
Study: NCT01495234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/BCP device
Description: The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/BCP device
Description: The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
Study: NCT03535077

Intervention type: OTHER
Intervention: Diagnostic Test
Description: Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy
Study: NCT04428983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hericium erinaceus mycelium
Description: Hericium erinaceus capsules 3 tables per day for 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hericium erinaceus mycelium
Description: Hericium erinaceus capsules 3 tables per day for 24 months
Study: NCT02303002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Intramuscular injection (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Intramuscular injection (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Intramuscular injection (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator botulinum toxin
Description: IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: IM injection
Study: NCT02646189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2139-Ca
Description: REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zadaxin
Description: Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
Study: NCT00282828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Study: NCT06625359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa in conditioning before transplantation
Description: For patients with ECOG PS 0 or 1 For patients with ECOG PS 0 or 1 and age \&lt; 60 years old, conditioning regimen before autologous stem cell transplantation consists of thiotepa, bulsulfan, and cyclophosphamide from day -9. Beginning on day -9 and through day -7, each patient was treated with thiotepa (200mg/m m2 IV per day). On days -6 to -4, patients received bulsulfan (2.7mg/kg IV over 3 hours per day every). Bulsulfan-related seizure prophylaxis was given with levetriacetam (1500mg loading on day -6, 500mg twice daily on days -5 to -3). On days -3 and -2, cyclophosphamide (60mg/kg IV per day) was given given.~Patients with ECOG PS 2 or age ≥ 60 years old received bulsulfan (3.2mg/kg IV over 3 hours per day for 2 days) resulting in 8 days regimen.
Study: NCT00282828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Study: NCT03045055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning.
Description: The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment.
Description: Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endovascular treatment.
Description: Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
Study: NCT01532583

Intervention type: OTHER
Intervention: Gynaecological examination, a supine stress test, questionnaires
Description: Gynaecological examination, a supine stress test, questionnaires
Study: NCT03695198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237 - SC
Description: LY3361237 administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237 - IV
Description: LY3361237 administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Placebo administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Placebo administered IV
Study: NCT03038945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2/0 barbed suture
Description: Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0/0 Vicryl suture
Description: Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
Study: NCT03053115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Cases will take liothyronine drops in the morning and two hours after dinner
Study: NCT03872388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients will receive Atorvastatin per ASCVD guidelines dosed as either a moderate intensity (20mg/day) or high intensity statin (80mg/day). Tablets are available in either 20mg or 80mg and will be dispensed as per standard of care for up to 24 months as part of the study.~Patients may also receive capecitabine concurrently with Atorvastatin per physician discretion as standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
Study: NCT03455296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid therapy; crystalloid
Description: maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A \& group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid therapy; crystalloid
Description: maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A \& group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.
Study: NCT03233061

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cardiorespiratory fitness and daily physical activities evaluations
Description: The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cardiorespiratory fitness and daily physical activities evaluations
Description: The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine.
Study: NCT00582530

Intervention type: OTHER
Intervention: Whole Blood Draw
Description: The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
Study: NCT04095221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: DOSE LEVELS FOR PATIENTS \> 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days~DOSE LEVELS FOR PATIENTS ≤ 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 15 mg/m2 IV daily x 10 days in 21 day cycles
Study: NCT01332396

Intervention type: DRUG
Intervention: Lapatinib
Study: NCT01899066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis, chemotherapy
Description: Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
Study: NCT01590771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg oral tablet once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to sitagliptin oral tablet once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gliclazide
Description: Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
Study: NCT02712671

Intervention type: RADIATION
Intervention: Chest radiograph
Description: A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
Study: NCT03024684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10mg daily
Study: NCT03053115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxin
Description: Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
Study: NCT03024684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo one tablet daily